PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Guidelines : Overactive bladder (adults)

Guidelines : Overactive bladder (adults)

Additional Documents

Other Drugs

Committee Recommendations

Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The following resources have been agreed by the APC to support patients in trialling a treatment break of their overactive bladder medicines:

  • Leaflet for trial of stopping anticholinergics
  • Leaflet for trial of stopping mirabegron

These resources can be found in the documents section.

06 September 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC recommend the management of overactive bladder and LUTS in line with CKS:

LUTS in men, https://cks.nice.org.uk/topics/luts-in-men/management/overactive-bladder/
Incontinence in women, Incontinence - urinary, in women | Health topics A to Z | CKS | NICE
 

Cost-effective treatment choices have been agreed locally as follows

  • Solifenacin 1st line

Swallowing difficulties:

  • Solifenacin Oral Suspension 1mg/ml Sugar Free
  • Oxybutynin Transdermal Patches (if oral route not suitable)

Contraindication or solifenacin not suitable - see Selection Tool for other treatment options

Stopping
Recommend that treatment of overactive bladder should be reviewed every 6-12 months with consideration of, or a trial of, discontinuation.
Switching
Recommend the switching from other anticholinergics prescribed for overactive bladder to one of the approved treatments which provide a very cost-effective range of products if clinically appropriate and following a discussion between the patient and the responsible
prescriber.

This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More